ClinConnect ClinConnect Logo
Search / Trial NCT03556891

Pivotal Study of eCoin for Overactive Bladder With Urgency Urinary Incontinence

Launched by VALENCIA TECHNOLOGIES CORPORATION · Jun 3, 2018

Trial Information

Current as of July 04, 2025

Completed

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Primary Inclusion Criteria:
  • 1. Women and men between 18 and 80 years old.
  • 2. Diagnosis of overactive bladder with urgency urinary incontinence or mixed urge and stress incontinence with a predominant urgency component (selfreported), for at least 6 months.
  • 3. Individual is without pharmacological treatment of overactive bladder (antimuscarinics and beta-3 agonists).
  • 4. Individual is intolerant of or has an inadequate response to any of anticholinergics, β3-adrenoceptor agonists, onabotulinumtoxinA, or percutaneous tibial nerve stimulation.
  • Primary Exclusion Criteria:
  • 1. Predominant stress urinary incontinence with more than 1/3 stress urinary incontinent episodes when compared to total urinary incontinent episodes.
  • 2. Clinically significant bladder outlet obstruction.
  • 3. Clinically significant pelvic organ prolapse beyond the hymenal ring.
  • 4. Inadequate skin integrity or any evidence of an infection or inflammation in either lower leg.

About Valencia Technologies Corporation

Valencia Technologies Corporation is a pioneering clinical trial sponsor focused on advancing innovative medical technologies to improve patient outcomes. With a commitment to excellence in research and development, Valencia Technologies specializes in the design and execution of clinical trials that address unmet medical needs across various therapeutic areas. The company leverages cutting-edge methodologies and a robust network of clinical sites to ensure rigorous study protocols, efficient data collection, and comprehensive analysis. Valencia Technologies is dedicated to fostering collaboration among stakeholders, including healthcare professionals and regulatory bodies, to accelerate the delivery of safe and effective treatments to patients worldwide.

Locations

San Diego, California, United States

Downey, California, United States

Greensboro, North Carolina, United States

Santa Barbara, California, United States

Columbia, South Carolina, United States

New York, New York, United States

Norwalk, Connecticut, United States

Owings Mills, Maryland, United States

Omaha, Nebraska, United States

Waterloo, Iowa, United States

Allentown, Pennsylvania, United States

Redwood City, California, United States

Englewood, Colorado, United States

Naples, Florida, United States

Skokie, Illinois, United States

Patients applied

0 patients applied

Trial Officials

Scott MacDiarmid, MD

Principal Investigator

Alliance Urology

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials